IOBTQ Stock Catalyst: IO Biotech Announced Topline Results from Phase 3 Trial of Cylembio Plus KEYTRUDA

Aug 11, 2025 · 5:31am ET

Clinical improvement in progression free survival observed but statistical significance narrowly missed.

Max move

+62.9%

High of day $3.29

Sparker timei

5:31am ET

IOBTQ · Aug 11, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

IO Biotech announced on 2025-08-11 IO Biotech announced topline results from a pivotal Phase 3 trial of Cylembio plus KEYTRUDA (pembrolizumab) for the treatment of first-line advanced melanoma, showing clinical improvement in progression free survival but narrowly missing statistical significance.

Median PFS (mPFS) of 19.4 months vs. 11.0 months. HR: 0.74 (CI 0.56-0.98) (nominal p=0.037). HR: 0.54 (CI 0.35-0.85) (nominal p=0.006). The announcement cited HR=0.77 (CI 0.58-1.00), (p=0.056), mPFS of 24.8 months vs. 11.0 months, mPFS of 16.6 months vs. 3.0 months, and HR=0.79 (CI 0.57-1.10).

IO Biotech, Inc. has a free float of 43,401,700 shares and 71,949,000 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time IOBTQ sparks.

Download Sniper App →

Catch the next IOBTQ-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →